#Paris #France #Terumo Neuro #SOFIA Flow 88 #Neurovascular

Terumo Neuro Launches SOFIA™ Flow 88 for Neurovascular Procedures

PARIS, June 2, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a fully owned subsidiary of Terumo Corporation, has officially announced the commercial availability of the SOFIA™ Flow 88 neurovascular aspiration catheter across EMEA. This new addition expands the company's stroke product offerings and is designed to enhance reliability and flexibility in neurovascular procedures.

The SOFIA™ Flow 88 catheter builds on over a decade of proven clinical performance and represents a significant advancement in neurovascular treatment options. With a large caliber design optimized for effectiveness, the catheter supports a wide array of medical procedures aimed at stroke management. The renowned SOFIA™ line has facilitated more than 500,000 procedures in over 170 countries, showcasing its reliability and trust in clinical settings worldwide.

Features and Innovations

The SOFIA™ Flow 88 features several patented engineering enhancements:

• - Confidence in Navigation: Optimized transition zones and a soft, atraumatic distal tip facilitate reliable tracking through intricate anatomies.
• - Proximal Stability: Designed for ease of use with both short and long sheaths during procedures.
• - Atraumatic Flexibility: Reinforced along its entire working length to minimize vascular trauma and ease navigation.
• - Effective Clot Capture: The patented SOFIA tip is engineered to expand beyond the marker band, effectively adapting to and capturing clots.
• - Integrity Maintained: The next-generation SOFIA technology incorporates nitinol braid and spiral reinforcement to preserve lumen integrity.

During the launch, Carsten Schroeder, CEO of Terumo Neuro, emphasized the importance of this innovative catheter. "With the introduction of the SOFIA™ Flow 88, we continue to stand on the solid foundation of trust established with our medical community over the past decade. This launch reflects our ongoing commitment to neurovascular innovation, aided by direct collaboration with physicians and our strong R&D capabilities. Together, we're making significant strides in stroke care to improve patient outcomes globally."

Integration with Existing Systems

The SOFIA™ Flow 88 is compatible with the SOFIA™ Plus 6F aspiration catheter, allowing for seamless integration into existing suction strategies. The efficacy, safety, and overall clinical outcomes have been validated through major clinical trials such as the SOFAST registry and the SESAME trial, which positions the SOFIA™ Plus 6F as a frontline method in treating large vessel occlusion strokes.

This new catheter complements Terumo Neuro's extensive range of stroke solutions, providing an integrated approach from aspiration, access, recovery to navigation:

• - SOFIA™ and SOFIA™ Plus Aspiration Catheters: Well-known for their superior traceability and clinical performance.
• - ERIC™ Retrieval Device: Purpose-built to enhance thrombus control and procedural efficiency.
• - BOBBY™ Balloon Guide Catheter: Designed for reliable flow occlusion during interventions with optimized compatibility.
• - WEDGE™ Microcatheter: Aids navigation while minimizing the outsized effect in the vascular system.
• - HEADWAY™ Microcatheters: Feature a low-profile outer diameter for enhanced versatility and prompt access.
• - TRAXCESS™ Guidewires: Designed with a soft tip for navigating challenging anatomies.

About Terumo Neuro

Formerly known as MicroVention, Inc., Terumo Neuro aims to innovate game-changing impact technologies in neurovascular treatments significantly. Established in 1997 and acquired by Terumo Corporation in 2006, the company offers over thirty products addressing cerebral aneurysms, ischemic strokes, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro's products are available in more than seventy countries through a direct sales force and strategic distribution partnerships. Manufacturing facilities are located in Aliso Viejo, California, and San Jose, Costa Rica.

For more information, please visit www.terumoneuro.com.

About Terumo Corporation

As a global leader in medical technology, Terumo Corporation (TSE:4543) has committed to contributing to society through healthcare for a century. With headquarters in Tokyo, Japan, and operations in over 160 countries and regions, Terumo employs more than 30,000 people focused on delivering innovative medical solutions in diverse healthcare settings. Starting as a thermometer manufacturer, the company now provides vascular intervention and cardiac surgery solutions, blood transfusions, cell therapy technology, and essential medical products for daily clinical practice. Terumo strives to maintain its value for patients, healthcare professionals, and society at large.